# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2008 Earnings Results

**Report date:** 2008-11-04 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2008

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Misses on EPS, Stock Down 0.55%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.27 | N/A | +15.89% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Defensive

Management expressed concerns about market conditions impacting performance. They remain committed to their research and development efforts.

**Key quotes:**

> Management acknowledged challenges in the current market environment.

> They emphasized ongoing investment in R&D despite the loss.

> The focus remains on long-term growth and pipeline development.

### Guidance Changes

No guidance was provided for future quarters.

### What It Means

The earnings report indicates that Regeneron faced challenges, leading to a loss in EPS. The stock reacted negatively, dropping 0.55%, reflecting investor concerns about the company's current performance and market conditions. However, the slight EPS beat suggests some resilience in their operations.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2008_